The company said total revenue for Q1 2024 fell to $167 million from $1.9 billion a year earlier, and that its GAAP net loss was $1.2 billion and its GAAP diluted loss per share was $(3.07).

1. 01

   The company said total revenue for Q1 2024 fell to $167 million from $1.9 billion a year earlier, and that its GAAP net loss was $1.2 billion and its GAAP diluted loss per share was $(3.07).

2. 02

   Moderna said it recorded $167 million in Spikevax sales in Q1, including $100 million in U.S. sales and $67 million internationally. The company cited lower sales of its COVID-19 vaccine as the reason net product sales fell 91% from a year earlier.

3. 03

   The company said cash, cash equivalents and investments were $12.2 billion as of March 31, 2024, down from $13.3 billion as of December 31, 2023. It cited research and development expenses and operating activities as the main drivers of the decrease.

4. 04

   The company reaffirmed its full-year 2024 respiratory franchise revenue outlook of approximately $4 billion. It said it now expects net sales of approximately $0.3 billion in the first half of the year and year-end cash and investments of approximately $9 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.